Ibalizumab

FDA label, Theratechnologies Inc., intravenous, effective 2026-01-07. Full label on DailyMed

Patient handout

Looking up MedlinePlus…

From MedlinePlus, U.S. National Library of Medicine

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using.

CD4-directed Blocking Antibody, Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor

Dosing in kidney impairment

This label has no separate kidney-impairment dosing section. Check warnings and clinical pharmacology in the full label.

Preparation and administration

Prepare this dose

Your numbers for ibalizumab. Take vial strength, diluent, and limits from the label below.

Basis

Enter a dose to see draw volume, final concentration, and rates.

Preparation Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard vial if solution is cloudy, if there is pronounced discoloration or if there is foreign particulate matter. See Table 1 for the appropriate number of vials required to prepare both the loading dose of 2,000 mg and the maintenance doses of 800 mg. [See table below.] TROGARZO solution for IV infusion or IV push should be prepared by a trained medical professional using aseptic technique as follows: For intravenous infusion For administration as an IV infusion, the appropriate number of vials are diluted in 250 mL of 0.9% Sodium Chloride Injection, USP.

Remove the flip-off cap from the single-dose vial and wipe the stopper with an alcohol swab.

Insert sterile syringe needle into the vial through the center of the stopper and withdraw 1.33 mL from each vial (NOTE: a small residual amount may remain in the vial, discard unused portion) and transfer into a 250 mL intravenous bag of 0.9% Sodium Chloride Injection, USP. Other intravenous diluents must not be used to prepare the TROGARZO solution for infusion.

Once diluted, the TROGARZO solution should be administered immediately.

If not administered immediately, store the diluted TROGARZO solution at room temperature (20°C to 25°C, 68°F to 77°F) for up to 4 hours, or refrigerated (2°C to 8°C, 36°F to 46°F) for up to 24 hours. If refrigerated, allow the diluted TROGARZO solution to stand at room temperature (20°C to 25°C, 68°F to 77°F) for at least 30 minutes but no more than 4 hours prior to administration.

Discard partially used vials or empty vials of TROGARZO and any unused portion of the diluted TROGARZO solution. For intravenous push For administration as an IV push, undiluted TROGARZO solution is administered.

Allow the vials to stand at room temperature for approximately 5 minutes.

Remove the flip-off cap from the single-dose vial and wipe the stopper with an alcohol swab.

Insert sterile syringe needle into the vial through the center of the stopper and withdraw 1.33 mL from each vial (NOTE: a small residual amount may remain in the vial, discard unused portion).

The undiluted TROGARZO solution should be administered immediately.

Discard partially used vials or empty vials of TROGARZO and any unused portion of the undiluted TROGARZO solution.

Administration TROGARZO solution should be administered by a trained medical professional. Administer TROGARZO intravenously (as an IV infusion or IV push) in the cephalic vein of the patients right or left arm. If this vein is not accessible, an appropriate vein located elsewhere can be used. Table 2 outlines the duration of IV infusion or IV push for the loading dose and maintenance dose. [See table below.] After the IV infusion is complete, flush with 30 mL of 0.9% Sodium Chloride Injection, USP.

After the IV push is complete, flush with 2 to 5 mL of 0.9% Sodium Chloride Injection, USP. All patients must be observed for 1 hour after completion of TROGARZO loading dose as an IV infusion or IV push. If the patient does not experience an infusion-associated adverse reaction, the post-administration observation time for the subsequent maintenance doses (IV infusion or IV push) can be reduced to 15 minutes.

If a maintenance dose (800 mg) of TROGARZO is missed by 3 days or longer beyond the scheduled dosing day, a loading dose (2,000 mg) should be administered as early as possible. Resume maintenance dosing (800 mg) every 14 days thereafter.

IV Infusion (Diluted) IV Push (Undiluted)
Loading Dose 2,000 mg Over at least 30 minutes Over at least 90 seconds
Maintenance Dose 800 mg Over at least 15 minutes Over at least 30 seconds
Table 1. Recommended TROGARZO Dose and Number of Vials Per Administration
TROGARZO Dose TROGARZO Vials (Total Volume to be Withdrawn)
Loading dose of 2,000 mg(IV infusion or undiluted IV push) 10 vials (13.3 mL)
Maintenance dose of 800 mg(IV infusion or undiluted IV push) 4 vials (5.32 mL)
Table 2. Duration of IV Infusion or IV Push
IV Infusion (Diluted)IV Push (Undiluted)
Loading Dose 2,000 mg Over at least 30 minutes Over at least 90 seconds
Maintenance Dose 800 mg Over at least 15 minutes Over at least 30 seconds

Contraindications

4 CONTRAINDICATIONS TROGARZO is contraindicated in patients with a prior hypersensitivity reaction to TROGARZO or any components of the product [see Warnings and Precautions ( 5.1 )]. Prior hypersensitivity reaction to TROGARZO or any components of the product.

Pregnancy and lactation

Pregnancy

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiretrovirals during pregnancy. This registry does not include Trogarzo, but likely includes patients’ concomitant antiretroviral drugs. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1–800–258–4263. Risk Summary Based on animal data, ibalizumab-uiyk use during pregnancy may cause reversible immunosuppression (CD4+ T cell and B cell lymphocytopenia) in infants exposed to ibalizumab-uiyk in utero.

Immunoglobulin G (IgG) antibodies, such as ibalizumab-uiyk, are transported across the placenta in significant amounts, especially near term; therefore, ibalizumab-uiyk has the potential to be transferred from the mother to the developing fetus (see Clinical Considerations). There are no available data on ibalizumab-uiyk use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S.

general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. In a reproductive study in monkeys, reversible decreases in CD4+ T cells and B cells and increases in CD8+ T cells were observed within the first 4 weeks after birth in infants born to pregnant monkeys receiving ibalizumab-uiyk intravenously ( see Data ). Lymphocyte counts returned to near normal levels by 3 months of age. One infant monkey died from a systemic viral infection that may be related to ibalizumab-uiyk-induced immunosuppression. No malformations or premature births were observed in this study.

Clinical Considerations Fetal/Neonatal Adverse Reactions Immunoglobulin G (IgG) antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester . Administration of TROGARZO during pregnancy may affect immune responses in the in utero-exposed infant. For infants with perinatal exposure to TROGARZO, immune phenotyping of the peripheral blood, including CD4+ T cell and B cell counts, is recommended. Expert consultation is also recommended to provide guidance on monitoring and management (e.g., need for antibiotic or immunoprophylaxis) of exposed infants based on the degree…

For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.

Supply and cost

Drug shortage status

Loading

Recalls (last 24 months)

Loading

Therapeutic equivalence (Orange Book)

Loading

Price ladder

Not the price at the counter
Loading

These are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.